Delving into the Latest Updates on Sucampo Pharma Americas LLC with Synapse

Overview

Tags

Digestive System Disorders

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CLCN2(Chloride channel protein 2)	1

ObjectiveThe efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response.MethodsIn the primary study, adults with OIC (fewer than three spontaneous bowel movements [SBMs] per week) were randomized to receive lubiprostone 24 mcg or placebo twice daily for 12 weeks. The primary end point was a change from baseline in the frequency of SBMs at week 8 in patients without a prior dose reduction. For the pooled analysis, the efficacy of lubiprostone was compared with placebo in patients receiving methadone or nonmethadone opioids. Responders were defined as patients with nine or more weeks of nonmissing SBM data who had one or more additional SBMs per week from baseline for each week that data were available and three or more SBMs per week for nine or more weeks.ResultsIn the primary study, the change from baseline at week 8 in SBM frequency was similar in the lubiprostone and placebo groups (P = 0.842). In the pooled analysis, the response rate was significantly higher with lubiprostone treatment vs placebo for patients receiving nonmethadone opioids (P = 0.002) but was similar between lubiprostone treatment and placebo in patients receiving methadone (P = 0.692). The safety profile of lubiprostone was unaffected by methadone use.ConclusionsThe phase 3 study did not meet its primary efficacy end point. However, analysis of pooled data from all phase 3 studies in the OIC clinical development program, stratified by methadone opioid usage, confirmed that lubiprostone is effective for treatment of OIC in patients taking nonmethadone opioids; no safety concerns were identified based on the type of opioid used.

01 Nov 2014·Value in HealthQ2 · MEDICINE

Which Metric To Choose For Indirect Comparison Of Treatments When Multiple Comparisons Are Feasible: Lubiprostone Verse Prucalopride In Chronic Constipation

Q2 · MEDICINE

Article

Author: Lichtlen, P ; Losch-Beridon, T ; Pennington, B ; Griffiths, A ; Hatswell, A J

100 Deals associated with Sucampo Pharma Americas LLC

Login to view more data

100 Translational Medicine associated with Sucampo Pharma Americas LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lubiprostone ( CLCN2 )	Irritable bowel syndrome with constipation More	Approved
Unoprostone Isopropyl ( PTGFR )	Glaucoma, Open-Angle More	Withdrawn
Cobiprostone ( CLCN2 )	Stomatitis More	Discontinued